Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. (CDIO)
Overview
Cardio Diagnostics Holdings, Inc. is a Chicago-headquartered, pre-commercial-scale diagnostics company developing AI-driven, epigenetics-based clinical tests for cardiovascular disease. Incorporated in Delaware, it became a public company through an October 2022 business combination and now trades on Nasdaq under CDIO, with a market capitalization of only about $6.1 million and trailing-twelve-month revenue of roughly $14,450 — figures that make clear the company is still in the earliest stages of commercialization. A 1-for-30 reverse stock split took effect on May 12, 2025, and the company employs a small team led by co-founders Dr. Timur Dogan (CEO) and Dr. Robert Philibert (Chief Medical Officer), who have spent more than a decade developing the underlying technology. As of the March 2026 filing date, only about 2.96 million shares were outstanding, and the company has funded operations partly through an at-the-market offering that raised roughly $3.9 million in gross proceeds during 2025, underscoring an early-stage company still working to convert scientific validation into meaningful revenue.
What They Do & How They Make Money
Cardio Diagnostics makes money — to the very limited extent it currently does — by selling laboratory-developed cardiovascular risk and diagnostic blood tests processed through its own newly established, CLIA-certified high-complexity laboratory (initial survey found "no deficiencies"). Its core technology is the proprietary AI-driven Multi-Omics Engine, which combines genetic biomarkers (SNPs, representing inherited risk that "drives less than 20% of the risk for cardiovascular disease" and does not change with intervention) with epigenetic biomarkers (DNA methylation patterns representing "acquired risk" that changes with lifestyle, environment, and treatment). This combination is the company's central scientific differentiator: rather than relying solely on static genetic risk, its tests aim to capture a patient's current, modifiable cardiovascular risk profile. Revenue realization depends heavily on insurance reimbursement, and the company achieved a key milestone when the American Medical Association awarded CPT PLA billing codes (0439U and 0440U) to its two flagship tests, with CMS assigning a final gapfill payment rate of $854 per test in December 2025 — though the company itself cautions that "the process to secure broad coverage could take years, which means that our ability to generate meaningful revenue will continue to be constrained."
Product Portfolio
- Epi+Gen CHD — Launched 2021; a three-year coronary heart disease event-risk blood test, which the company reports demonstrated 76%/78% sensitivity for men/women versus 44%/32% for traditional risk calculators in its validation studies.
- PrecisionCHD — Introduced March 2023; an integrated genetic-epigenetic blood test for detecting the presence of coronary heart disease, with reported validation-study performance of 82% AUC, 79% sensitivity, and 76% specificity.
- CardioInnovate360 — Launched May 2023; a research-use-only version of the platform sold to biopharmaceutical companies for drug discovery and validation work.
- HeartRisk — Announced February 2024; a population-level cardiovascular risk intelligence platform combining anonymized clinical, geographic, and industry data.
Competitors
Cardio Diagnostics faces competition across several categories: broader genetic testing panels, lipid-based clinical risk calculators (the ASCVD Risk Calculator/Pooled Cohort Equation, which the company itself describes as "perhaps the most direct competitor"), imaging-based approaches like coronary artery calcium CT screening, proteomic tests (C-reactive protein panels, CADhs, HART CVE), and emerging wearable-device-based risk monitoring, though the company notes wearables currently have "low" clinical market penetrance. It acknowledges that "some of our potential and current competitors have longer operating histories and have, or will have, substantially greater financial, technical, research, and other resources than we do."
Competitive Position
Cardio Diagnostics' most durable asset is intellectual property: a patent portfolio spanning seven patent families, including two issued U.S. patents and international patents across ten countries, plus an exclusive license from the University of Iowa Research Foundation for its core epigenetic-biomarker IP (expiring 2037 and 2041). This gives the company real scientific differentiation and a long runway of IP protection around its dual genetic-epigenetic testing approach — a genuine moat if commercialization succeeds. But that IP advantage is currently unmonetized: with only about $14,450 in trailing revenue, a $6.1 million market cap, sales cycles as long as 24 months, and dependence on slow, uncertain payer reimbursement expansion beyond the initial CMS gapfill rate, the company remains a speculative, pre-revenue-scale story rather than an operating business with proven pricing power or switching costs. Its go-to-market strategy — targeting innovative health systems, physician-directed concierge practices, self-insured employers, and telemedicine channels through exclusivity agreements meant to foreclose distribution to competitors — could eventually build real switching-cost stickiness if adopted at scale, but that remains aspirational. The company's path forward depends entirely on converting its patented, clinically validated technology into broad payer coverage and provider adoption before its limited cash resources are exhausted.